Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'
May 23, 2018 12:44 PM EDTH.C. Wainwright raised its price target on Cara Therapeutics (NASDAQ: CARA) to $24.00 (from $22.00) while maintaining a Neutral rating.
... MoreCara Therapeutics (CARA) PT Raised to $20 at Stifel Following Vifor-Fresenius JV
May 23, 2018 11:01 AM EDTStifel raised its price target on Cara Therapeutics (NASDAQ: CARA) to $20.00 (from $17.00) while maintaining a Buy rating after the company announced a licensing arrangement with Vifor Fresenius Medical Care Renal Pharma (VFMCRP)a joint venture between Vifor Pharma (market leading provider of renal drugs) and... More
Cara Therapeutics (CARA) Bullish View Reiterated at Laidlaw Following Licence Agreement with Vifor Fresenius Medical
May 23, 2018 11:00 AM EDTLaidlaw analyst Francois Brisebois reiterated a Buy rating and $26 price target on Cara Therapeutics (NASDAQ: CARA) after the company announced that they have licensed worldwide rights (except US, Japan and South Korea) to commercialize Korsuva injection for the treatment of CKD-aP in dialysis patients to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
Brisebois commented, "We are encouraged by the financial implications of the licensing as CARA will receive an upfront... More
Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License Agreement
May 23, 2018 10:26 AM EDTNeedham & Company analyst Alan Carr reiterated a Buy rating and $23 price target on Cara Therapeutics (NASDAQ: CARA) after the company announced this morning a license and co-promotion agreement with Vifor Fresenius Medical Care Renal Pharma (VF).
Carr commented, "The agreement relates... More
